13F HOLDINGS REPORT
CAXTON CORP
Quarter ended Q4 2025 · Filed February 13, 2026 · Accession 0000919574-26-000956
Total Value
$4.3M
Positions
11
Other Managers
0
Confidential Omitted
Yes
Holdings (11)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | SPDR GOLD TR | GLD | 6,964 | $2.8M | 64.50% |
| 2 | BERKSHIRE HATHAWAY INC DEL | BRK-A | 710 | $356,771 | 8.34% |
| 3 | SPYRE THERAPEUTICS INC | SYRE | 8,919 | $292,194 | 6.83% |
| 4 | MIND MEDICINE MINDMED INC | 60255C885 | 15,688 | $210,058 | 4.91% |
| 5 | KYVERNA THERAPEUTICS INC | KYTX | 18,773 | $176,468 | 4.12% |
| 6 | COMPASS THERAPEUTICS INC | CMPX | 29,495 | $158,386 | 3.70% |
| 7 | LEXEO THERAPEUTICS INC | LXEO | 13,943 | $138,453 | 3.24% |
| 8 | X4 PHARMACEUTICALS INC | XFOR | 15,557 | $62,227 | 1.45% |
| 9 | INHIBIKASE THERAPEUTICS INC | IKT | 28,453 | $58,328 | 1.36% |
| 10 | SAB BIOTHERAPEUTICS INC | SABSW | 10,527 | $39,371 | 0.92% |
| 11 | CONTEXT THERAPEUTICS INC | CNTX | 18,403 | $27,053 | 0.63% |